Stereological analysis of hippocampus in rat treated with chemotherapeutic agent oxaliplatin

Authors: J. Sadeghinezhad, I. Amrein

DOI: 10.5603/FM.a2020.0031

Article type: ORIGINAL ARTICLES

Submitted: 2019-12-12

Accepted: 2020-01-27

Published online: 2020-03-11

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Folia Morphologica" are listed in PubMed.
Stereological analysis of hippocampus in rat treated with chemotherapeutic agent oxaliplatin

Running title: Hippocampus after oxaliplatin treatment

J. Sadeghinezhad1, I. Amrein2
1Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
2Institute of Anatomy, Division of Functional Neuroanatomy, University of Zurich, Zurich, Switzerland; Department of Health Sciences and Technology, ETH, Zurich, Switzerland

Address for correspondence: Dr. Javad Sadeghinezhad, Associated professor, PhD, Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tehran, P.O. Box: 14155-6453, Tehran, Iran, tel: +98-21-61117116, fax: +98-21-66933222, e-mail: Sadeghinezhad@ut.ac.ir

Abstract

Background: Oxaliplatin (OX) has been widely used for treatment of colorectal and other cancers. Adverse effect of OX and other anticancer agents on cognition have been reported, but studies on the effects of chemotherapy on brain structure are scarce. This study describes the morphometrical features of the hippocampus structures in rat following OX treatment using design-based stereological methods.

Materials and methods: Ten male Wistar rats were randomized into two groups. The rats from OX group received 2.4 mg/kg OX in vehicle for five consecutive days every week for 2 weeks intraperitoneally (IP). Controls received vehicle only. Cavalieri ‘s method and the optical fractionator method were used for volume and neuron estimation, respectively.

Results: Cavalieri ‘s method was used for to estimate volume and showed that the
volume of the hippocampus was significantly decreased in OX group (31.84 ± 1.24 mm$^3$) compared with the vehicle control group (36.95 ± 3.48 mm$^3$). The optical fractionator method was used to estimate neuron number and showed that the number of neurons in dentate gyrus, cornu ammonis 1 and 3 in OX group (8.147 ± 2.84 × 10$^5$, 4.257 ± 0.59 × 10$^5$ and 2.133 ± 0.22 × 10$^5$, respectively) did not differ from those of vehicle control group (7.36 ± 1.42 × 10$^5$, 3.521 ± 0.54 × 10$^5$ and 1.989 ± 0.46 × 10$^5$, respectively).

**Conclusions:** These findings suggested that OX treatment induce loss of hippocampal volume without neuronal loss which might help to clarify the mechanism by which OX affects cognition and to improve preventive treatment strategies.

**Key words:** stereology, hippocampus, oxaliplatin, chemotherapy, rat

**Introduction**

Chemotherapy in many cancer types have increased survival times in patients. However, cognitive dysfunctions, referred to as “chemobrain”, such as impairments in attention and concentration, verbal and visual memory and processing speed have been reported after systemic chemotherapy [7,41]. There are numerous reports regarding adverse effect of different anticancer agents like methotrexate [29,37,42,46], 5-fluorouracil [8,11], cyclophosphamide [9,36], doxorubicin [23,27], paclitaxel [19], vincristine [5,35] and cytosine arabinoside [26] on cognition in human and animal experimental models. Chemotherapy agents, which inhibit tumor cell proliferation, can also effect on non-tumor cell proliferation in the brain [7].

Oxaliplatin (OX) is a third-generation platinum drug which has been widely used alone or with other chemotherapeutic agents for treatment of colorectal cancer and other carcinomas including ovarian, breast and lung cancers [34,40]. It is able to react with DNA to create DNA intrastrand adducts, which block DNA synthesis and induce apoptosis in cancer cells and rapidly dividing cells [43]. OX induces peripheral neuropathy [38], crosses the blood-brain barrier and accumulates in cerebrospinal and extracellular fluid in the brain [17,18], which indicates that the drug can have a direct effect on brain function and structure. Treatment with OX has been shown to induce
cognitive impairment in laboratory animals [9,10,39]. Furthermore, cellular damage in the hippocampus has been related to the loss of memory function in rats following OX administration [4,7]. Other platinum compounds such as cisplatin, have also been reported to produce cognitive dysfunction and central neurological problems [28,48].

The hippocampus, as the key structure in learning and the formation of memory is an appropriate site for investigating the mechanisms involved in some of the cognitive problems arisen by the chemotherapeutic agents [4].

Designed-base stereology enables unbiased and precise quantitative analysis of three-dimensional structures [15]. It is one of the important techniques for the morphometrical evaluation of the hippocampus, which contain important information about the memory function [14]. The morphometrical features of the hippocampus following chemotherapy have not been thoroughly investigated using stereology. Assessment of the effect of OX on hippocampus volume using Cavalieri 's method and neuronal number in different regions of the hippocampus using optical dissector/fractionator, as a gold standard for efficient, unbiased number estimation in neuroscience, may contribute to evaluate the risks of the treatment and possibly help improve preventive strategies.

MATERIALS AND METHODS

Animals- Ten adult (12-15 weeks) male Wistar rats (Pasteur Institute, Tehran, Iran) were used for the experiment. Animals were housed in large acrylic cages with free access to food and water under controlled light (12 h light and dark cycle) and temperature (22 ±2 °C). The rats were allowed to acclimatize for one week before experimentation. All experimental procedures involving animals in this study were conducted in accordance with the standard guide for the care and use of laboratory animals of the University of Tehran, Tehran, Iran.

Drug administration- Rats were randomly divided into OX-treated and vehicle control groups. The rats from OX group received 2.4 mg/kg OX dissolved in 5% glucose solution (vehicle) for five consecutive days per week for 2 weeks intraperitoneally (IP) and the vehicle control was administrated 5% glucose solution.
The chosen dose of OX was in accordance with that commonly used for neurotoxic evaluation of the agent in previous animal studies [4].

*Tissue sampling and stereological methods* - Rats were euthanized 21 days after treatment using thiopental (50 mg/kg IP). Then, transcardial perfusion fixation of the animals was done using 10% formalin. The brains were removed and the left hemisphere of each animal was fixed in same fixative, dehydrated and embedded in glycol methacrylate (Technovit 7100, Heraeus Kulzer GmbH, Wehrheim/Ts, Germany) according to the manufacturer's instructions.

Embedded brains were cut frontally using a rotary microtome with 20 micrometer thickness. Every 20th section was collected using the principle of systematic uniform random sampling, which is known as the section sampling fraction (ssf = 1/20). On average, this sampling scheme provided 13 (11-15) sections per animal. Sections were mounted, dried and stained in Giemsa solution [16].

Hippocampal volume and principal cell numbers were estimated using StereoInvestigator 10 software (MBF Bioscience, Williston, VT, USA). The hippocampus including dentate gyrus (DG) and cornu ammonis (CA) were determined in the sections using rat brain atlas of Paxinos and Watson (1986). DG were recognized due to horseshoe-shape with small and densely packed neurons. The CA2 region in this study was considered as belong to the CA3 region because the CA2 is very small and the boundaries between these two regions are not detectable. The border between the CA3 and CA1 is defined by a small transition zone between the two regions [21] (Fig. 1).

*Estimation of the volume*- Estimation of total volume of the hippocampus was done using test points on each section (Fig. 2a). The volume was estimated by Cavalieri estimator using the following equation [15]: 

\[ V = \Sigma P \cdot \text{ssf} \cdot T \cdot (a/p) \]

where \(\Sigma P\) is the total number of points hitting the structure; \(\text{ssf} (1/20)\) is the section sampling fraction; \(T (20 \mu m)\) is the section thickness and \(a/p (9 \cdot 10^4 \mu m^2)\) represents the area per point.

*Estimation of the number of neurons* - The optical fractionator was used for number estimation of pyramidal cells and granular cells in CA and DG, respectively. First, the contours of the dentate gyrus and the CA1 and CA3 regions were delineated at low magnification. Then, selected regions were analyzed by systematic random
sampling at high magnification. A known fraction of each section was assessed by moving the microscope motorized stage in regular step length in x and y directions and applying an unbiased counting frame sized to count the neurons of specific region (Fig. 2b).

For DG, a step length of 180 μm and counting frame size of 12 × 12 μm was used, for CA1 a step length of 240 μm and frame size of 20 × 20 μm, and for CA3 a step length of 190 μm and frame size of 24 × 24 was applied. The counting frame was focused through 10 μm of the section thickness, which corresponds to disector height. Section thickness was measured at every 4-5 sampling location.

The total number of cells in the granular cells (DG) and pyramidal cells (CA1 and CA3) in the left hemisphere was calculated using the following formula [6,32]:

\[ N = \frac{1}{SSF} \cdot \frac{1}{ASF} \cdot \frac{1}{HSF} \cdot \sum Q' \]

where \( HSF = \frac{h}{t_Q} \)

for \( t_Q = \frac{\sum t_i q_i}{\sum q_i} \)

\( \sum Q' \) : total count of particles sampled; \( SSF \) : the section sample fraction; \( ASF \) : the area sample fraction (frame size/ x,y step length); \( Hsf \) : the height sampling fraction; \( h \) : the disector height (10 μm in this study); \( t_Q \) : the number-weighted mean section thickness; \( t_i \) : the section thickness in the ith counting frame with a cell count of \( q_i \) in the disector.

**Statistical analysis** - The coefficient of error (CE) of the volume and the number estimates was calculated as previously described [13]. T-test was used for statistical analysis. A value of \( p < 0.05 \) was considered significant.

**RESULTS**

The results showed that the volume of the hippocampus was significantly decreased after OX treatment compared with the vehicle control group (\( p < 0.05 \)). The related volume of hippocampus in OX-treated and vehicle control group was 31.84 ± 1.24 mm³ and 36.95 ± 3.48 mm³, respectively (Table 1). The number of neurons in DG, CA1 and CA3 did not show any significant difference between the two groups. The neuronal number of DG, CA1 and CA3 in the OX-treated group was estimated to be 8.147 ± 2.84 × 10⁵, 4.257 ± 0.59 × 10⁵ and 2.133 ± 0.22 × 10⁵ respectively, while the related neurons in vehicle control group accounted 7.36 ± 1.42 × 10⁵, 3.521 ± 0.54 ×
$10^5$ and $1.989 \pm 0.46 \times 10^5$, respectively (Table 1). The CE$^2$/CV$^2$ ratios (Table 1) are typically $>0.5$ indicating that group variances are dominated by the inter-animal differences with only minor contributions of measurement variance to the group variance.

**DISCUSSION**

The hippocampus is pivotal for learning and the formation of memory in the brain. Since the hippocampus shows various forms of plasticity, including the formation of new nerve cells in adult animals, it may be affected by the chemotherapeutic drugs leading to cognitive deficit [25].

In the present study, stereological techniques were used for the quantification of volume and number of neurons of the hippocampus following OX treatment in rat. The results of the current experiment demonstrated that treatment with OX caused a reduction in total volume of the hippocampus. Considering that oxaliplatin penetrates the blood brain barrier and accumulates in the brain [17,18], an effect on the hippocampus is plausible and may explain memory impairment and other cognitive dysfunctions that have been found in previous studies using behavioral tests [9,10,39].

Similar to our results, magnetic resonance imaging (MRI) studies showed a reduced hippocampus volume in breast cancer survivors exposed to chemotherapy [1,3,22]. In contrast, Yoshikawa et al. [47], found no adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors using MRI. They implied that brain regions other than the hippocampus, such as the prefrontal cortex, might be involved in memory impairment after chemotherapy.

The neuron numbers did not show any significant loss of either granular cells of the DG or pyramidal cells of the CA1 and CA3 following OX treatment in rat. OX has been reported to induce apoptotic pathway in hippocampus with increasing caspase-3 and caspase-9 [4]. Cyclophosphamide chemotherapy has been suggested to suppress hippocampal neurogenesis and interrupt hippocampal function in mice [45]. Methotrexate also showed inhibition of the formation of immature neurons in the hippocampus [12,44]. It is interesting that although hippocampal neuronal loss has been explained well in Alzheimer diseases, Joelving et al. [20] did not find any significant
loss of neuron in Parkinson's disease. Korbo et al. [24] also reported no loss of hippocampal neurons in non-Alzheimer dementia.

It should be mentioned that reduction in the number of neurons is not the only mechanism that affect neuronal function. Structurally, decreasing dendritic branching or losing synapses may impair neuronal function without neuronal loss [1]. Changes in hippocampal transmitters and signal transduction pathways are other mechanisms that may disturb hippocampal function [30,31]. These findings suggest that cognitive disorders may be associated with a variety of changes that may not necessarily include a change in neuronal cell number [20].

It is important to note that the estimating neuron number based on 2-D counting is potentially biased. In our study, the potential bias was avoided by the use of the optical fractionator, which is a combination of fractionator sampling and the optical dissector principle. This unbiased stereological method is not influenced by tissue deformation like shrinkage or swelling. Importantly, it is also unaffected by changes in the shape or size of the cells that are being counted. The optical fractionator is the gold-standard method for estimating number of neurons [14,24].

This study is the first description of an effect of oxaliplatin on the rat hippocampus using stereology. In conclusion, the results of the present study showed that OX treatment induces a decrease of hippocampal volume without neuronal loss. These findings might help to clarify the mechanism by which OX affects cognition by crossing the blood-brain barrier and accumulating in cerebrospinal and extracellular fluid in the brain and promote the development of treatment strategies that minimize cognitive side effects.

Acknowledgments

The authors would like to thank Prof. David Wolfer and Dr. Lutz Slomianka for their excellent scientific collaboration.

References

1. Apple AC, Ryals AJ, Alpert KI, et al. Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns. Neuroimage Clin. 2017; 14: 685-691, doi: 10.1016/j.nicl.2017.03.004.
2. Barnes CA, Rao G, Houston FP. LTP induction threshold change in old rats at the perforant path-granule cell synapse. Neurobiol Aging. 2000; 21(5): 613-620, doi: 10.1016/s0197-4580(00)00163-9.

3. Bergouignan L, Lefranc JP, Chupin M, et al. Breast cancer affects both the hippocampus volume and the episodic autobiographical memoryretrieval. PLoS One. 2011; 6(10): e25349. doi: 10.1371/journal.pone.0025349.

4. Bianchi E, Di Cesare Mannelli L, Micheli L, et al. Apoptotic process induced by Oxaliplatin in rat hippocampus causes memory impairment. Basic Clin Pharmacol Toxicol. 2017; 120(1): 14-21. doi: 10.1111/bcpt.12629.

5. Di Patre PL, Abbamondi A, Bartolini L, et al. GM1 ganglioside counteracts cholinergic and behavioral deficits induced in the rat by intracerebral injection of vincristine. Eur J Pharmacol. 1989; 162(1): 43-50, doi: 10.1016/0014-2999(89)90602-x.

6. Dorph-Petersen KA, Nyengaard JR, Gundersen HJ. Tissue shrinkage and unbiased stereological estimation of particle number and size. J Microsc 2001; 204(Pt 3): 232-246, doi: 10.1046/j.1365-2818.2001.00958.x.

7. Dubois M, Lapinte N, Villier V, et al. Chemotherapy-induced long term alteration of executive functions and hippocampal cellproliferation: role of glucose as adjuvant. Neuropharmacology. 2014; 79: 234-248, doi: 10.1016/j.neuropharm.2013.11.012.

8. ElBeltagy M, Mustafa S, Umka J, et al. Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. Behav Brain Res. 2010; 208(1): 112-117, doi: 10.1016/j.bbr.2009.11.017.

9. Fardell JE, Vardy J, Shah JD, et al. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl). 2012; 220(1): 183-193, doi: 10.1007/s00213-011-2466-2.

10. Fardell JE, Vardy J, Monds LA, et al. The long term impact of oxaliplatin chemotherapy on rodent cognition and peripheralneuropathy. Behav Brain Res. 2015; 291: 80-88, doi: 10.1016/j.bbr.2015.04.038.

11. Foley JJ, Raffa RB, Walker EA. Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology (Berl). 2008; 199(4): 527-538, doi: 10.1007/s00213-008-1175-y.
12. Goncalves MB, Williams EJ, Yip P, et al. The COX-2 inhibitors, meloxicam and nimesulide, suppress neurogenesis in the adult mousebrain. Br J Pharmacol. 2010; 159(5): 1118-1125, doi: 10.1111/j.1476-5381.2009.00618.x.

13. Gundersen HJ, Jensen EB, Kiêu K, et al. The efficiency of systematic sampling in stereology-reconsidered. J Microsc. 1999; 193(Pt 3): 199-211, doi: 10.1046/j.1476-2818.1999.00457.x.

14. Hosseini-Sharifabad M, Nyengaard JR. Design-based estimation of neuronal number and individual neuronal volume in the rat hippocampus. J Neurosci Methods. 2007; 162(1-2): 206-214, doi: 10.1016/j.jneumeth.2007.01.009.

15. Howard V, Reed MG. Unbiased stereology: three-dimensional measurement in microscopy. BIOS Scientific Publishers, Taylor & Francis Group, New York 2005.

16. Iñiguez C, Gayoso MJ, Carreres J. A versatile and simple method for staining nervous tissue using Giemsa dye. J Neurosci Methods. 1985; 13(1): 77–86, doi: 10.1016/0165-0270(85)90045-7.

17. Jacobs SS, Fox E, Dennie C, et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res. 2005; 11(4): 1669-1674, doi: 10.1158/1078-0432.CCR-04-1807.

18. Jacobs S, McCully CL, Murphy RF, et al. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Canc Chemother Pharmacol. 2010; 65(5): 817–824, doi: 10.1007/s00280-009-1085-7.

19. Janelins MC, Roscoe JA, Berg MJ, et al. IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adultC57BL/6 mice. Cancer Invest. 2010; 28(5): 544-553, doi: 10.3109/07357900903405942.

20. Joelving FC, Billeskov R, Christensen JR, et al. Hippocampal neuron and glial cell numbers in Parkinson's disease--a stereological study. Hippocampus. 2006; 16(10): 826-833, doi: 10.1002/hipo.20212.

21. Kaæe SS, Chen F, Wegener G, et al. Quantitative hippocampal structural changes following electroconvulsive seizure treatment in a rat model of depression. Synapse. 2012; 66(8): 667-676, doi: 10.1002/syn.21553.

22. Kesler S, Janelins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-
alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013; 30(Suppl): S109-116, doi: 10.1016/j.bbi.2012.05.017.
23. Konat GW, Kraszpulski M, James I, et al. Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis. 2008; 23(3): 325-333, doi: 10.1007/s11011-008-9100-y.
24. Korbo L, Amrein I, Lipp HP, et al. No evidence for loss of hippocampal neurons in non-Alzheimer dementia patients. Acta Neurol Scand. 2004; 109(2): 132-139, doi: 10.1034/j.1600-0404.2003.00182.x.
25. Li J, Li Y, Su H, et al. The influence of environment stimulation on learning and memory function in rats with medication chemotherapy. Conf Proc IEEE Eng Med Biol Soc. 2018; 2018: 3537-3540, doi: 10.1109/EMBC.2018.8513084.
26. Li CQ, Liu D, Huang L, et al. Cytosine arabinoside treatment impairs the remote spatial memory function and induces dendritic retraction in the anterior cingulate cortex of rats. Brain Res Bull. 2008; 77(5): 237-240, doi: 10.1016/j.brainresbull.2008.07.010.
27. Liedke PE, Reolon GK, Kilpp B, et al. Systemic administration of doxorubicin impairs aversively motivated memory in rats. Pharmacol Biochem Behav. 2009; 94(2): 239-243, doi: 10.1016/j.pbb.2009.09.001.
28. Lomeli N, Di K, Czerniawski J, et al. Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radic Biol Med. 2017; 102: 274-286, doi: 10.1016/j.freeradbiomed.2016.11.046.
29. Madhyastha S, Somayaji SN, Rao MS, et al. Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol. 2002; 80(11): 1076-1084, doi: 10.1139/y02-135.
30. Marksteiner J, Lechner T, Kaufmann WA, et al. Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer's disease. Acta Neuropathol. 2000; 100(2): 205-212, doi: 10.1007/s004010000239.
31. Nowakowski C, Kaufmann WA, Adlassnig C, et al. Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia. Schizophr Res. 2002; 58(1): 43-53, doi: 10.1016/s0920-9964(01)00389-9.
32. Olesen MV, Needham EK, Pakkenberg B. The optical fractionator technique to estimate cell numbers in a rat model of electroconvulsive therapy. J Vis Exp. 2017; doi:10.3791/55737.

33. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Elsevier, Amsterdam 2007.

34. Park JH, Chae J, Roh K, et al. Oxaliplatin-Induced Peripheral Neuropathy via TRPA1 Stimulation in Mice Dorsal Root GanglionIs Correlated with Aluminum Accumulation. PLoS One. 2015; doi: 10.1371/journal.pone.0124875.

35. Rebert CS, Pryor GT, Frick MS. Effects of vincristine, maytansine, and cis-platinum on behavioral and electrophysiologicalindices of neurotoxicity in the rat. J Appl Toxicol. 1984; 4(6): 330-338, doi: 10.1002/jat.2550040610.

36. Reiriz AB, Reolon GK, Preissler T, et al. Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamamide in mice. Clin Cancer Res. 2006; 12(16): 5000-5001, doi: 10.1158/1078-0432.CCR-06-0138.

37. Seigers R, Schagen SB, Beerling W, et al. Long lasting suppression of hippocampal cell proliferation and impaired cognitive performanceby methotrexate in the rat. Behav Brain Res. 2008; 186(2): 168-175, doi: 10.1016/j.bbr.2007.08.004.

38. Sprowl JA, Ciarimboli G, Lancaster CS, et al. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013; 110(27): 11199-11204, doi: 10.1073/pnas.1305321110.

39. Sharpe MJ, Fardell JE, Vardy J, et al. The chemotherapy agent oxaliplatin impairs the renewal of fear to an extinguished conditionedstimulus in rats. Behav Brain Res. 2012; 227(1): 295-299, doi: 10.1016/j.bbr.2011.11.005.

40. Ueno T, Endo K, Hori K, et al. Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexaneplatinum (II)-incorporating micelles (NC-4016). Int J Nanomedicine. 2014; 9: 3005-3012, doi: 10.2147/IJN.S60564.

41. Vardy J, Tannock I. Cognitive function after chemotherapy in adults with solid tumours. Crit Rev Oncol Hematol. 2007; 63(3): 183-202, doi: 10.1016/j.critrevonc.2007.06.001.
42. Winocur G, Vardy J, Binns MA, et al. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav. 2006; 85(1): 66-75, doi: 10.1016/j.pbb.2006.07.010.

43. Wafai L, Taher M, Jovanovska V, et al. Effects of oxaliplatin on mouse myenteric neurons and colonic motility. Front Neurosci. 2013; 7: 30, doi: 10.3389/fnins.2013.00030.

44. Yang M, Kim JS, Kim J, et al. Acute treatment with methotrexate induces hippocampal dysfunction in a mouse model of breast cancer. Brain Res Bull. 2012; 89(1-2): 50-56, doi: 10.1016/j.brainresbull.2012.07.003.

45. Yang M, Kim JS, Song MS, et al. Cyclophosphamide impairs hippocampus dependent learning and memory in adult mice: Possible involvement of hippocampal neurogenesis in chemotherapy-induced memory deficits. Neurobiol Learn Mem. 2010; 93(4): 487-494, doi: 10.1016/j.nlm.2010.01.006.

46. Yanovski JA, Packer RJ, Levine JD, et al. An animal model to detect the neuropsychological toxicity of anticancer agents. Med Pediatr Oncol. 1989; 17(3): 216-221, doi: 10.1002/mpo.2950170309.

47. Yoshikawa E, Matsuoka Y, Inagaki M, et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancersurvivors. Breast Cancer Res Treat. 2005; 92(1): 81-84, doi: 10.1007/s10549-005-1412-6.

48. Zhou W, Kavelaars A, Heijnen CJ. Metformin Prevents Cisplatin-Induced Cognitive Impairment and Brain Damage in Mice. PLoS One. 2016; doi: 10.1371/journal.pone.0151890.

Table 1. Estimated hippocampal volume and neuron number.

|                              | OX-treated group | Vehicle treated group | p value |
|------------------------------|------------------|-----------------------|---------|
|                              | Mean ± SD        | CE        | CV   | Mean ± SD        | CE | CV   |         |
| Total volume (mm³)           | 31.84 ± 1.24     | 0.02      | 0.03 | 36.95 ± 3.48     | 0.02 | 0.09 | 0.01   |
| Granular cell number (10⁵)  | 7.36 ± 1.42      | 0.11      | 0.19 | 8.147 ± 2.84     | 0.11 | 0.34 | 0.69   |
Pyramidal cell number in CA1 (10^5)  3.521 ± 0.54  0.11  0.15  4.257 ± 0.59  0.1  0.13  0.19
Pyramidal cell number in CA3 (10^5)  1.989 ± 0.46  0.12  0.23  2.133 ± 0.22  0.12  0.1  0.33

Mean ± SD of hippocampal volume and neurons from one hemisphere (five animals in each group) estimates with CE (= SEM/mean; intera-animal coefficient of error) and CV (= SD/mean; observed inter-animal coefficient of variation). Different superscript letters in the same rows indicate a significant difference, p < 0.05.

**Figure 1.** Histological coronal section of the hippocampus (scale bar= 200 µm) with magnification of the CA1, CA3 and DG (scale bar= 500 µm). Arrowhead mark boundary between CA1 and CA3.

**Figure 2.** Stereological method for estimating hippocampal volume and neuronal number. (a): Example of a point grid on histological section of the hippocampus. The total number of points hitting the whole hippocampus was counted. (b): Example of an unbiased counting frame used for optical dissector method. The cells which their nucleolus came into focus within dissector’s height if they were completely inside the counting frame or touched the accepted lines (green lines) were counted. Here one neuron (asterisk) was counted (scale bar= 200 µm).
